While IL-6 and myostatin are persistently elevated, contributing to systemic inflammation, insulin resistance, and muscle wasting, CTSB typically decreases in metabolic disorders such as OB and T2DM, which may potentially impair lysosomal homeostasis and attenuate neuroprotective signaling along the muscle–brain axis. Here, CTSB is linked to metabolic disease.